Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Merger & Restructuring Worth ₹335 Cr

Emcure Pharma announced that its subsidiary Marcan will acquire Mantra Pharma for CAD $50 million (≈ ₹335 Crore). The acquisition makes Mantra a wholly‑owned step‑down subsidiary of Marcan.

Value

₹335.0 Cr

Emcure Pharmaceuticals Management Change

Mr. Kuber Jagdale, President - API Business, superannuated from Emcure Pharmaceuticals on June 30, 2026. This resulted in a change of senior management.

Emcure Pharmaceuticals Share Pledge

Emcure Pharmaceuticals reports that promoter group member Smita Paresh Shah pledged 60,000 equity shares. The shares remain pledged as of March 31, 2026.

Emcure Pharmaceuticals Employee Stock Options

Emcure Pharmaceuticals allotted 70,000 equity shares following ESOP exercises. This increases the company's issued and paid-up share capital to 18,96,59,547 equity shares.

Emcure Pharmaceuticals Other Announcement

Emcure Pharmaceuticals Limited submitted its Annual Secretarial Compliance Report for FY2026. The report by Mehta & Mehta confirms full regulatory compliance with no adverse observations.

Emcure Pharmaceuticals Business Update

Emcure Pharmaceuticals concluded a US FDA inspection at its Sanand facility with seven procedural observations. The company will address these within the stipulated timeframe.